Novartis AG Eyes Consumer, Veterinary Purchases Up to $3 Billion, Chief Says

Novartis AG (NOVN) is willing to spend up to $3 billion on acquisitions of consumer-health or veterinary assets to bolster the drugmaker’s undersized businesses in those areas, Chief Executive Officer Joe Jimenez said.

Novartis also would consider generic-drug, biotechnology or diagnostics purchases, Jimenez said in an interview yesterday at the company’s Basel, Switzerland, headquarters. There’s a dearth of available assets, he said.

“We do expect to make bolt-on acquisitions to these five platforms, and we could do that today,” Jimenez, 51, said. “And when I say bolt-on, I mean anything from $1 billion to $3 billion.” He declined to comment on possible targets or the timing of potential purchases.

Back to news